{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:03:09Z","timestamp":1785787389010,"version":"3.56.0"},"publisher-location":"New York, NY","reference-count":48,"publisher":"Springer New York","isbn-type":[{"value":"9781493968671","type":"print"},{"value":"9781493968695","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-1-4939-6869-5_9","type":"book-chapter","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T09:58:42Z","timestamp":1491213522000},"page":"151-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Development of Recombinant Measles Virus-Based Vaccines"],"prefix":"10.1007","author":[{"given":"Michael D.","family":"M\u00fchlebach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","unstructured":"Griffin DE (2002) Measles virus. In: Wiley encyclopedia of molecular medicine. John Wiley & Sons, Inc., Hoboken, NJ, USA","DOI":"10.1002\/0471203076.emm0739"},{"issue":"7","key":"9_CR2","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1086\/528993","volume":"197","author":"I Davidkin","year":"2008","unstructured":"Davidkin I, Jokinen S, Broman M et al (2008) Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 197(7):950\u2013956. doi:\n                    10.1086\/528993","journal-title":"J Infect Dis"},{"issue":"5\u20136","key":"9_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0264-410X(01)00384-X","volume":"20","author":"MR Hilleman","year":"2001","unstructured":"Hilleman MR (2001) Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 20(5\u20136):651\u2013665","journal-title":"Vaccine"},{"key":"9_CR4","unstructured":"WHO Global eradication of measles. Sixty-Third World Health Assembly"},{"issue":"23","key":"9_CR5","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","volume":"14","author":"F Radecke","year":"1995","unstructured":"Radecke F, Spielhofer P, Schneider H et al (1995) Rescue of measles viruses from cloned DNA. EMBO J 14(23):5773\u20135784","journal-title":"EMBO J"},{"issue":"9","key":"9_CR6","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","volume":"72","author":"B Mrkic","year":"1998","unstructured":"Mrkic B, Pavlovic J, Rulicke T et al (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72(9):7420\u20137427","journal-title":"J Virol"},{"issue":"1","key":"9_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","volume":"78","author":"C Lorin","year":"2004","unstructured":"Lorin C, Mollet L, Delebecque F et al (2004) A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78(1):146\u2013157","journal-title":"J Virol"},{"issue":"36","key":"9_CR8","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","volume":"31","author":"S Brandler","year":"2013","unstructured":"Brandler S, Ruffie C, Combredet C et al (2013) A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31(36):3718\u20133725. doi:\n                    10.1016\/j.vaccine.2013.05.086","journal-title":"Vaccine"},{"issue":"5","key":"9_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer K, Schwameis M, Firbas C et al (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5):519\u2013527. doi:\n                    10.1016\/S1473-3099(15)70043-5","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"9_CR10","doi-asserted-by":"publisher","first-page":"10597","DOI":"10.1128\/JVI.00923-07","volume":"81","author":"JR Valle del","year":"2007","unstructured":"del Valle JR, Devaux P, Hodge G et al (2007) A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81(19):10597\u201310605. doi:\n                    10.1128\/JVI.00923-07","journal-title":"J Virol"},{"issue":"17","key":"9_CR11","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1128\/JVI.00906-09","volume":"83","author":"J Reyes-del Valle","year":"2009","unstructured":"Reyes-del Valle J, Hodge G, McChesney MB et al (2009) Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J Virol 83(17):9013\u20139017. doi:\n                    10.1128\/JVI.00906-09","journal-title":"J Virol"},{"issue":"6","key":"9_CR12","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","volume":"73","author":"M Singh","year":"1999","unstructured":"Singh M, Cattaneo R, Billeter MA (1999) A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73(6):4823\u20134828","journal-title":"J Virol"},{"issue":"16","key":"9_CR13","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","volume":"25","author":"A Zuniga","year":"2007","unstructured":"Zuniga A, Wang Z, Liniger M et al (2007) Attenuated measles virus as a vaccine vector. Vaccine 25(16):2974\u20132983. doi:\n                    10.1016\/j.vaccine.2007.01.064","journal-title":"Vaccine"},{"issue":"17\u201319","key":"9_CR14","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/S0264-410X(00)00523-5","volume":"19","author":"Z Wang","year":"2001","unstructured":"Wang Z, Hangartner L, Cornu TI et al (2001) Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19(17\u201319):2329\u20132336","journal-title":"Vaccine"},{"key":"9_CR15","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000523","author":"C Swett-Tapia","year":"2016","unstructured":"Swett-Tapia C, Bogaert L, de Jong P et al (2016) Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines. J Gen Virol. doi:\n                    10.1099\/jgv.0.000523","journal-title":"J Gen Virol"},{"issue":"2","key":"9_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/infdis\/jis328","volume":"206","author":"S Brandler","year":"2012","unstructured":"Brandler S, Marianneau P, Loth P et al (2012) Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J Infect Dis 206(2):212\u2013219. doi:\n                    10.1093\/infdis\/jis328","journal-title":"J Infect Dis"},{"issue":"2","key":"9_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1086\/426824","volume":"191","author":"P Despres","year":"2005","unstructured":"Despres P, Combredet C, Frenkiel M-P et al (2005) Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191(2):207\u2013214. doi:\n                    10.1086\/426824","journal-title":"J Infect Dis"},{"issue":"1","key":"9_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.virol.2009.02.047","volume":"388","author":"M Guerbois","year":"2009","unstructured":"Guerbois M, Moris A, Combredet C et al (2009) Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388(1):191\u2013203. doi:\n                    10.1016\/j.virol.2009.02.047","journal-title":"Virology"},{"issue":"11","key":"9_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050397","volume":"7","author":"R Stebbings","year":"2012","unstructured":"Stebbings R, Fevrier M, Li B et al (2012) Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One 7(11):e50397. doi:\n                    10.1371\/journal.pone.0050397","journal-title":"PLoS One"},{"issue":"51","key":"9_CR20","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1016\/j.vaccine.2013.09.072","volume":"31","author":"R Stebbings","year":"2013","unstructured":"Stebbings R, Li B, Lorin C et al (2013) Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Vaccine 31(51):6079\u20136086. doi:\n                    10.1016\/j.vaccine.2013.09.072","journal-title":"Vaccine"},{"issue":"12","key":"9_CR21","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00210-012-0793-4","volume":"385","author":"C Lorin","year":"2012","unstructured":"Lorin C, Segal L, Mols J et al (2012) Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn Schmiedebergs Arch Pharmacol 385(12):1211\u20131225. doi:\n                    10.1007\/s00210-012-0793-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"36","key":"9_CR22","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1016\/j.vaccine.2005.04.024","volume":"23","author":"C Lorin","year":"2005","unstructured":"Lorin C, Delebecque F, Labrousse V et al (2005) A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36):4463\u20134472. doi:\n                    10.1016\/j.vaccine.2005.04.024","journal-title":"Vaccine"},{"issue":"17","key":"9_CR23","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.vaccine.2008.01.057","volume":"26","author":"M Liniger","year":"2008","unstructured":"Liniger M, Zuniga A, Tamin A et al (2008) Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26(17):2164\u20132174. doi:\n                    10.1016\/j.vaccine.2008.01.057","journal-title":"Vaccine"},{"issue":"7","key":"9_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1080\/21645515.2016.1143576","volume":"12","author":"H-M Hu","year":"2016","unstructured":"Hu H-M, Chen H-W, Hsiao Y-J et al (2016) The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother 12(7):1678\u20131689. doi:\n                    10.1080\/21645515.2016.1143576","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"9_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/vaccines3030503","volume":"3","author":"IS Harahap-Carrillo","year":"2015","unstructured":"Harahap-Carrillo IS, Ceballos-Olvera I, Valle JR-D (2015) Immunogenic subviral particles displaying domain III of dengue 2 envelope protein vectored by measles virus. Vaccines (Basel) 3(3):503\u2013518. doi:\n                    10.3390\/vaccines3030503","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"9_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000096","volume":"1","author":"S Brandler","year":"2007","unstructured":"Brandler S, Lucas-Hourani M, Moris A et al (2007) Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 1(3):e96. doi:\n                    10.1371\/journal.pntd.0000096","journal-title":"PLoS Negl Trop Dis"},{"issue":"41","key":"9_CR27","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1016\/j.vaccine.2010.07.073","volume":"28","author":"S Brandler","year":"2010","unstructured":"Brandler S, Ruffie C, Najburg V et al (2010) Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28(41):6730\u20136739. doi:\n                    10.1016\/j.vaccine.2010.07.073","journal-title":"Vaccine"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","volume":"452\u2013453","author":"N Escriou","year":"2014","unstructured":"Escriou N, Callendret B, Lorin V et al (2014) Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology 452\u2013453:32\u201341. doi:\n                    10.1016\/j.virol.2014.01.002","journal-title":"Virology"},{"key":"9_CR29","doi-asserted-by":"publisher","unstructured":"Lininger M, Zuniga A, Morin TNA et al. (2009) Recombinant measles virus exp ressing single or multiple antigens of human immunodeficiency virus (HIV-1) in duce cellular and humoral immune responses. Vaccine 27(25\u201326):3299\u20133305. doi:\n                    10.1016\/j.vaccine.2009.01.057","DOI":"10.1016\/j.vaccine.2009.01.057"},{"key":"9_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.07.051","author":"G Gupta","year":"2016","unstructured":"Gupta G, Giannino V, Rishi N et al (2016) Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine. Vaccine. doi:\n                    10.1016\/j.vaccine.2016.07.051","journal-title":"Vaccine"},{"issue":"25\u201326","key":"9_CR31","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2009.01.061","volume":"27","author":"G Cantarella","year":"2009","unstructured":"Cantarella G, Liniger M, Zuniga A et al (2009) Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27(25\u201326):3385\u20133390. doi:\n                    10.1016\/j.vaccine.2009.01.061","journal-title":"Vaccine"},{"issue":"6","key":"9_CR32","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.cimid.2010.02.006","volume":"33","author":"M Satoh","year":"2010","unstructured":"Satoh M, Saito M, Tanaka K et al (2010) Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD\/Scid\/Jak3null mouse. Comp Immunol Microbiol Infect Dis 33(6):e81\u2013e88. doi:\n                    10.1016\/j.cimid.2010.02.006","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"21","key":"9_CR33","doi-asserted-by":"publisher","first-page":"11558","DOI":"10.1128\/JVI.01776-12","volume":"86","author":"J Reyes-del Valle","year":"2012","unstructured":"Reyes-del Valle J, de La Fuente C, Turner MA et al (2012) Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 86(21):11558\u201311566. doi:\n                    10.1128\/JVI.01776-12","journal-title":"J Virol"},{"issue":"8","key":"9_CR34","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.vaccine.2010.12.020","volume":"29","author":"ID Iankov","year":"2011","unstructured":"Iankov ID, Haralambieva IH, Galanis E (2011) Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 29(8):1710\u20131720. doi:\n                    10.1016\/j.vaccine.2010.12.020","journal-title":"Vaccine"},{"issue":"7","key":"9_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.vaccine.2010.12.028","volume":"29","author":"A Sawada","year":"2011","unstructured":"Sawada A, Komase K, Nakayama T (2011) AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 29(7):1481\u20131490. doi:\n                    10.1016\/j.vaccine.2010.12.028","journal-title":"Vaccine"},{"issue":"35","key":"9_CR36","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1016\/j.vaccine.2014.06.024","volume":"32","author":"Y Yamaji","year":"2014","unstructured":"Yamaji Y, Nakayama T (2014) Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 32(35):4529\u20134536. doi:\n                    10.1016\/j.vaccine.2014.06.024","journal-title":"Vaccine"},{"key":"9_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1874357901206010012","volume":"6","author":"H Mok","year":"2012","unstructured":"Mok H, Cheng X, Xu Q et al (2012) Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol J 6:12\u201322. doi:\n                    10.2174\/1874357901206010012","journal-title":"Open Virol J"},{"issue":"22","key":"9_CR38","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1128\/JVI.01815-15","volume":"89","author":"AH Malczyk","year":"2015","unstructured":"Malczyk AH, Kupke A, Prufer S et al (2015) A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89(22):11654\u201311667. doi:\n                    10.1128\/JVI.01815-15","journal-title":"J Virol"},{"issue":"1","key":"9_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2222\/jsv.64.105","volume":"64","author":"M Yoneda","year":"2014","unstructured":"Yoneda M (2014) Study of pathogenicity of Nipah virus and its vaccine development. Uirusu 64(1):105\u2013112. doi:\n                    10.2222\/jsv.64.105","journal-title":"Uirusu"},{"issue":"3","key":"9_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150213","volume":"11","author":"A Higuchi","year":"2016","unstructured":"Higuchi A, Toriniwa H, Komiya T et al (2016) Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus. PLoS One 11(3):e0150213. doi:\n                    10.1371\/journal.pone.0150213","journal-title":"PLoS One"},{"issue":"5","key":"9_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nm0502-527","volume":"8","author":"K-W Peng","year":"2002","unstructured":"Peng K-W, Facteau S, Wegman T et al (2002) Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8(5):527\u2013531. doi:\n                    10.1038\/nm0502-527","journal-title":"Nat Med"},{"issue":"5","key":"9_CR42","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","volume":"103","author":"D Dingli","year":"2004","unstructured":"Dingli D, Peng K-W, Harvey ME et al (2004) Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103(5):1641\u20131646. doi:\n                    10.1182\/blood-2003-07-2233","journal-title":"Blood"},{"key":"9_CR43","doi-asserted-by":"publisher","unstructured":"Excler J-L, Delvecchio CJ, Wiley RE et al (2016) Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14\u201315, 2015. Emerg Infect Dis 22(8). doi:\n                    10.3201\/eid2208.160229","DOI":"10.3201\/eid2208.160229"},{"issue":"7","key":"9_CR44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.4131","volume":"22","author":"K Modjarrad","year":"2016","unstructured":"Modjarrad K, Moorthy VS, Ben Embarek P et al (2016) A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med 22(7):701\u2013705. doi:\n                    10.1038\/nm.4131","journal-title":"Nat Med"},{"issue":"1","key":"9_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0166-0934(96)02137-4","volume":"64","author":"H Schneider","year":"1997","unstructured":"Schneider H, Spielhofer P, Kaelin K et al (1997) Rescue of measles virus using a replication-deficient vaccinia-T7 vector. J Virol Methods 64(1):57\u201364","journal-title":"J Virol Methods"},{"issue":"12","key":"9_CR46","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1128\/JVI.02389-05","volume":"80","author":"A Martin","year":"2006","unstructured":"Martin A, Staeheli P, Schneider U (2006) RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 80(12):5708\u20135715. doi:\n                    10.1128\/JVI.02389-05","journal-title":"J Virol"},{"issue":"8","key":"9_CR47","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1128\/JVI.67.8.4822-4830.1993","volume":"67","author":"P Calain","year":"1993","unstructured":"Calain P, Roux L (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67(8):4822\u20134830","journal-title":"J Virol"},{"issue":"4","key":"9_CR48","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF01863914","volume":"162","author":"G K\u00e4rber","year":"1931","unstructured":"K\u00e4rber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 162(4):480\u2013483. doi:\n                    10.1007\/BF01863914","journal-title":"Arch Exp Pathol Pharmakol"}],"container-title":["Methods in Molecular Biology","Recombinant Virus Vaccines"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-6869-5_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T14:27:25Z","timestamp":1584455245000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-6869-5_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9781493968671","9781493968695"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-6869-5_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"4 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}